非小细胞肺癌患者表皮生长因子受体突变和蛋白表达水平的研究  

Study on EGFR-mutation and expression in non-small cell lung cancer patients

作　　者：陈韦[1,2] 冯华松[2] 韩志海[2] 聂舟山[2] 刘振千[2] 孟激光[2] 张燕[2] 

机构地区：[1]第四军医大学西京医院呼吸内科,西安710032 [2]中国人民解放军海军总医院呼吸内科,北京100048

出　　处：《中国肿瘤临床与康复》2014年第7期782-785,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的评价非小细胞肺癌患者组织表皮生长因子受体(epithelial growth factor receptor,EGFR)突变与EGFR蛋白表达水平的相关性及临床应用价值。方法采用突变富集液相芯片技术和免疫组织化学方法分别检测60例非小细胞肺癌组织中EGFR 19、18、21和20外显子基因突变和EGFR蛋白表达水平,对检测结果进行相关性分析。结果突变富集液相芯片检测显示,EGFR外显子19和21的突变率为26.7%(16/60);免疫组化检测EGFR蛋白表达为50.0%(30/60),两者呈正相关(r=0.676,P=0.0001)。结论突变富集液相芯片技术检测非小细胞肺癌组织EGFR突变与免疫组织化学检测的EGFR蛋白表达水平具有较好的相关性,两者互为补充,对于预测EGFR-TKI的生存获益具有更大的价值。Objective To explore the correlation between the epidermal growth factor recaptor（ EG- FR） mutation and gene expression. Methods We collected 60 patients with non-small cell lung cancer, from July 2012 to September 2013. To detect the EGFR-mutation （E19,E18,E21 ,E20）by mutant-enriched liquid chip technology and gene expression by IHC respectively. Results The rates of EGFR-mutation de- tected by mutant-enriched liquid chip technology were 26. 7% （16/60）and the expression levels tested by IHC were 50.0% （ 30/60 ） . A significant correlationship was observed between them （ r = 0. 676, P = 0. 0001 ）. Conclusion The EGFR-mutation（ El9 ,E21 ）by mutant-enriched liquid chip technology were con- sistent with gene expression by IHC. The complementary use of mutant-enriched liquid chip technology and IHC can extend the lives of patients with eating tyrosine kinase inhibitor（TKI）.

关 键 词：癌 非小细胞肺 表皮生长因子受体 突变富集液相芯片 免疫组织化学 

分 类 号：R734.2[医药卫生—肿瘤]